REGN

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

07/19 06:09 am

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

07/14 04:47 am

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

06/20 10:47 am

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

06/15 11:22 am

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

06/15 11:22 am

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

06/15 11:21 am

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

06/13 04:22 pm

Rheumatoid Arthritis Global Market Research Report 2025-2035: TNF Inhibitors, IL-6 Inhibitors, and JAK Inhibitors at the Forefront of Developing Biologic Therapies

06/10 04:53 am

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

06/07 06:30 pm

Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?

06/01 11:16 am

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

05/31 08:04 am

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data

05/30 08:30 am

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

05/30 01:00 am

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

05/30 01:00 am

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO

05/30 01:00 am

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.

05/29 05:30 am

Prurigo Nodularis Market - Global and Regional Analysis and Forecasts 2025-2035 | Advancements in Biologic Therapies Revolutionize Prurigo Nodularis Treatment

05/26 10:53 am

Does the 23andMe Acquisition Make Regeneron a Buy Now?

05/24 05:31 am

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market Sales

05/23 04:49 am

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

05/22 05:00 pm

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

05/22 08:15 am

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

05/19 07:07 am

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

05/15 08:48 am

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight

05/12 01:00 pm

Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments

05/07 11:00 am

Giants of Cancer Care® announces the 13th annual class of inductees

05/07 09:00 am

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold

04/26 09:30 am

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

04/22 06:00 am

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market

04/18 04:26 am

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

04/17 12:06 pm

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study

04/15 02:08 pm

Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline

04/10 05:59 am

Is Vertex Pharmaceuticals Stock a Buy?

04/08 09:45 am

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years

04/05 03:23 am

Why Pharma and Biotech Stocks Got Thrashed on Tuesday

03/25 06:47 pm

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

03/11 09:32 pm

REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN

03/10 04:47 pm

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

03/10 12:50 pm

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

03/09 06:20 am

Regeneron’s (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman

03/06 02:53 pm

Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight

03/06 02:00 pm

Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

03/05 01:00 pm

Physicians’ Education Resource® unveils Retina Resource, a comprehensive educational hub for retina specialists and eye care professionals

03/05 11:00 am

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

03/04 05:00 pm

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman

03/02 02:11 pm

REGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN

03/01 04:13 pm

REGN 最終截止日期：全國知名投資者法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 Regeneron Pharmaceuticals, Inc. 投資者在對 REGN 提出證券集體訴訟的重要截止日期 3 月 10 日前聘請律師

03/01 04:13 pm

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month

03/01 09:45 am

OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight

02/28 02:00 pm

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

02/28 08:00 am